Global Trends and Burden of Diabetes Mellitus (DM): A Comprehensive Review of Epidemiology, Risk Factors, Health Disparities, and Future Projections
Abstract
Background: Diabetes mellitus (DM) represents one of the most pressing global public health challenges, with rapidly increasing prevalence, substantial morbidity and mortality, and profound socioeconomic consequences. The rising burden of diabetes is driven by demographic transitions, lifestyle changes, urbanization, and persistent health inequities, particularly in low- and middle-income countries.
Objective: The worldwide health problem known as diabetes mellitus (DM) affects people through its growing prevalence which leads to severe health problems and death while creating major economic difficulties for society. The increasing diabetes burden results from demographic shifts and changes in physical activity patterns and the development of cities and the ongoing existence of health disparities which mainly affect people in low- and middle-income nations.
Methodology: The review aims to create a complete summary of existing research which examines diabetes mellitus (DM) global patterns and its impact on different regions and identifies primary risk factors and assesses the disease impact and current clinical trials and patent research and future preventive methods and treatment strategies. The researchers performed a narrative literature review by utilizing major scientific databases together with official global health reports from the World Health Organization and International Diabetes Federation and Global Burden of Disease study. The researchers examined and combined peer-reviewed articles together with epidemiological studies and clinical trial data and pertinent patent documents which had been published in the last few years.
Results: Diabetes affects people in all parts of the world but shows different patterns of occurrence and death rates and life years lost to disability. People in low-resource areas experience higher disease burden because they face two main problems: they receive medical treatment too late and they cannot afford healthcare services and they lack economic resources. People who develop this condition face key risk factors which include obesity and lack of physical activity and bad eating habits and their increasing age and their genetic risk factors.
Conclusion: DM poses a substantial and escalating global health burden. Addressing its impact requires coordinated public health policies, equitable healthcare delivery, continued clinical innovation, and sustained research efforts to improve outcomes and reduce disparities worldwide.
Keywords:
Diabetes mellitus, epidemiology, risk factors, health disparities, clinical trials, patentsDOI
https://doi.org/10.22270/jddt.v16i5.7761References
1. Saxena S, Saxena R, Singh AP, Maurya NK. Metabolic reasons of diabetes mellitus: an update. Int J Clin Biochem Res. 2024;11:8-11. https://doi.org/10.18231/j.ijcbr.2024.002
2. Nadhiya J, Vijayalakshmi MK, Showbharnikhaa S. A brief review on diabetes mellitus. Journal of Pharma Insights and Research. 2024 Feb 7;2(1):117-21.
3. Powers AC, Niswender KD, Evans-Molina C. Diabetes mellitus: diagnosis, classification, and pathophysiology. Diabetes. 2022;1000:415.
4. Shaikh AA, Kolhatkar MK, Sopane DR, Thorve AN. Review on: Diabetes mellitus is a disease. International Journal of research in Pharmaceutical sciences. 2022 Mar 23;13(1):102-9. https://doi.org/10.26452/ijrps.v13i1.27
5. Mohajan D, Mohajan HK. Basic concepts of diabetics mellitus for the welfare of general patients. Studies in Social Science & Humanities. 2023 Jun 20;2(6):23-31. https://doi.org/10.56397/SSSH.2023.06.03
6. Marruganti C, Suvan JE, D'Aiuto F. Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity. Periodontology 2000. 2023 Oct 16. https://doi.org/10.1111/prd.12536 PMid:37845800
7. Blagov A, Nedosugova L, Kirichenko T, Sukhorukov V, Melnichenko A, Orekhov A. Mitochondrial dysfunction as a factor of energy metabolism disorders in type 2 diabetes mellitus. Front Biosci (Schol Ed). 2024 Mar 8;16(1):5. https://doi.org/10.31083/j.fbs1601005 PMid:38538341
8. Borovcanin MM, Vesic K, Petrovic I, Jovanovic IP, Mijailović NR. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders. World Journal of Diabetes. 2023 May 15;14(5):481. https://doi.org/10.4239/wjd.v14.i5.481 PMid:37273248 PMCid:PMC10236997
9. Aloke C, Egwu CO, Aja PM, Obasi NA, Chukwu J, Akumadu BO, Ogbu PN, Achilonu I. Current advances in the management of diabetes mellitus. Biomedicines. 2022 Sep 29;10(10):2436. https://doi.org/10.3390/biomedicines10102436 PMid:36289697 PMCid:PMC9599361
10. Bodke H, Wagh V, Kakar G, WAGH V. Diabetes mellitus and prevalence of other comorbid conditions: a systematic review. Cureus. 2023 Nov 24;15(11). https://doi.org/10.7759/cureus.49374
11. Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes mellitus and cardiovascular disease: exploring epidemiology, pathophysiology, and treatment strategies. Reviews in Cardiovascular Medicine. 2024 Dec 11;25(12):436. https://doi.org/10.31083/j.rcm2512436 PMid:39742220 PMCid:PMC11683709
12. Garg P, Duggal N. Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review. Obesity Medicine. 2022 Oct 1;35:100459. https://doi.org/10.1016/j.obmed.2022.100459
13. Grisi DC, Vieira IV, de Almeida Lima AK, de Oliveira Mattos MC, Damê-Teixeira N, Salles LP, De Oliveira LA, Stefani C, do Carmo Machado Guimarães M. The complex interrelationship between diabetes mellitus, oral diseases and general health. Current Diabetes Reviews. 2022 Mar 1;18(3):8-22. https://doi.org/10.2174/1573399817666210322153210 PMid:34225632
14. Balooch Hasankhani M, Mirzaei H, Karamoozian A. Global trend analysis of diabetes mellitus incidence, mortality, and mortality-to-incidence ratio from 1990 to 2019. Scientific Reports. 2023 Dec 11;13(1):21908. https://doi.org/10.1038/s41598-023-49249-0 PMid:38081899 PMCid:PMC10713611
15. Pan C, Cao B, Fang H, Liu Y, Zhang S, Luo W, Wu Y. Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics. Frontiers in Endocrinology. 2025 Jul 1;16:1596127. https://doi.org/10.3389/fendo.2025.1596127 PMid:40666058 PMCid:PMC12259457
16. Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022 Sep;77(3):444-54. https://doi.org/10.1007/s12020-022-03125-5 PMid:35841511
17. Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, Shaw JE, Paciorek CJ, Singleton RK, Pires AB, Stevens GA. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet. 2024 Nov 23;404(10467):2077-93.
18. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes mellitus. 2023 May 14;26(2):104-23. https://doi.org/10.14341/DM13035
19. Yameny AA. Diabetes mellitus overview 2024. Journal of Bioscience and Applied Research. 2024 Sep 28;10(3):641-5. https://doi.org/10.21608/jbaar.2024.382794
20. Hossain MJ, Al‐Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports. 2024 Mar;7(3):e2004. https://doi.org/10.1002/hsr2.2004 PMid:38524769 PMCid:PMC10958528
21. Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping knowledge landscapes and emerging trends of the links between bone metabolism and diabetes mellitus: a bibliometric analysis from 2000 to 2021. Frontiers in public health. 2022 Jun 3;10:918483. https://doi.org/10.3389/fpubh.2022.918483 PMid:35719662 PMCid:PMC9204186
22. Bodke H, Wagh V, Kakar G, WAGH V. Diabetes mellitus and prevalence of other comorbid conditions: a systematic review. Cureus. 2023 Nov 24;15(11). https://doi.org/10.7759/cureus.49374
23. Su B, Wang Y, Dong Y, Hu G, Xu Y, Peng X, Wang Q, Zheng X. Trends in diabetes mortality in urban and rural China, 1987-2019: a joinpoint regression analysis. Frontiers in endocrinology. 2022 Jan 17;12:777654. https://doi.org/10.3389/fendo.2021.777654 PMid:35111135 PMCid:PMC8801697
24. Gregory GA, Robinson TI, Linklater SE, Wang F, Colagiuri S, de Beaufort C, Donaghue KC, Harding JL, Wander PL, Zhang X, Li X. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. The lancet Diabetes & endocrinology. 2022 Oct 1;10(10):741-60. https://doi.org/10.1016/S2213-8587(22)00218-2 PMid:36113507
25. Bellia A, Meloni M, Andreadi A, Uccioli L, Lauro D. Geographic and ethnic inequalities in diabetes-related amputations. Frontiers in clinical diabetes and healthcare. 2022 Mar 11;3:855168. https://doi.org/10.3389/fcdhc.2022.855168 PMid:36992760 PMCid:PMC10012100
26. Pan C, Cao B, Fang H, Liu Y, Zhang S, Luo W, Wu Y. Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics. Frontiers in Endocrinology. 2025 Jul 1;16:1596127. https://doi.org/10.3389/fendo.2025.1596127 PMid:40666058 PMCid:PMC12259457
27. Yedjou CG, Sims JN, Njiki S, Chitoh AM, Joseph M, Cherkos AS, Tchounwou PB. Health and racial disparities in diabetes mellitus prevalence, management, policies, and outcomes in the United States. Journal of community medicine & public health. 2024 Aug 15;8(3):460. https://doi.org/10.29011/2577-2228.100460 PMid:39697180 PMCid:PMC11654833
28. Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022 Sep;77(3):444-54. https://doi.org/10.1007/s12020-022-03125-5 PMid:35841511
29. Lobo JM, Kang H, Brennan MB, Kim S, McMurry TL, Balkrishnan R, Anderson R, McCall A, Sohn MW. Regional and racial disparities in major amputation rates among medicare beneficiaries with diabetes: a retrospective study in the southeastern USA. BMJ Public Health. 2023 Dec 12;1(1). https://doi.org/10.1136/bmjph-2023-000206 PMid:38764700 PMCid:PMC11101188
30. Hassan S, Gujral UP, Quarells RC, Rhodes EC, Shah MK, Obi J, Lee WH, Shamambo L, Weber MB, Narayan KV. Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward. The lancet Diabetes & endocrinology. 2023 Jul 1;11(7):509-24. https://doi.org/10.1016/S2213-8587(23)00129-8 PMid:37356445 PMCid:PMC11070656
31. Alqahtani B, Elnaggar RK, Alshehri MM, Khunti K, Alenazi A. National and regional prevalence rates of diabetes in Saudi Arabia: analysis of national survey data. International Journal of Diabetes in Developing Countries. 2023 Jun;43(3):392-7. https://doi.org/10.1007/s13410-022-01092-1
32. Hossain MJ, Al‐Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports. 2024 Mar;7(3):e2004. https://doi.org/10.1002/hsr2.2004 PMid:38524769 PMCid:PMC10958528
33. Hazar N, Jokar M, Namavari N, Hosseini S, Rahmanian V. An updated systematic review and Meta-analysis of the prevalence of type 2 diabetes in Iran, 1996-2023. Frontiers in public health. 2024 Apr 4;12:1322072. https://doi.org/10.3389/fpubh.2024.1322072 PMid:38638475 PMCid:PMC11025666
34. Syarifuddin S, Samosir W. Characteristics of types of diabetes mellitus II in regional general hospital than rondahaim, simalungun district. Medalion Journal: Medical Research, Nursing, Health and Midwife Participation. 2022 Dec 31;3(4):144-8. https://doi.org/10.59733/medalion.v3i4.64
35. Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Frontiers in public health. 2025 Jan 23;13:1515797. https://doi.org/10.3389/fpubh.2025.1515797 PMid:39916706 PMCid:PMC11798972
36. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JC, Mbanya JC, Pavkov ME. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022 Jan 1;183:109119. https://doi.org/10.1016/j.diabres.2021.109119 PMid:34879977 PMCid:PMC11057359
37. Burnside MJ, Williman JA, Davies HM, Jefferies CA, Paul RG, Wheeler BJ, Wiltshire EJ, Anderson YC, De Bock MI. Inequity in access to continuous glucose monitoring and health outcomes in paediatric diabetes, a case for national continuous glucose monitoring funding: a cross-sectional population study of children with type 1 diabetes in New Zealand. The Lancet Regional Health-Western Pacific. 2023 Feb 1;31. https://doi.org/10.1016/j.lanwpc.2022.100644 PMid:36419466 PMCid:PMC9676142
38. Kang PS, Neeland IJ. Body fat distribution, diabetes mellitus, and cardiovascular disease: an update. Current cardiology reports. 2023 Nov;25(11):1555-64. https://doi.org/10.1007/s11886-023-01969-5 PMid:37792133
39. Yom S, Lor M. Advancing health disparities research: the need to include Asian American subgroup populations. Journal of racial and ethnic health disparities. 2022 Dec;9(6):2248-82. https://doi.org/10.1007/s40615-021-01164-8 PMid:34791615 PMCid:PMC8598103
40. Murtaza G, Riaz S, Zafar M, Ahsan Raza M, Kaleem I, Imran H, Al-Harbi AT, Sabouri A, Asim Niaz T, Bashir S. Examining the growing challenge: Prevalence of diabetes in young adults. Medicine International. 2024 Nov 6;5(1):2. https://doi.org/10.3892/mi.2024.201 PMid:39563945 PMCid:PMC11571047
41. Almohmadi NH, Tiwari A, Chaudhary T, Ekta, Sindhu RK, Babu MA, Yassen AS, Alexiou A, Papadakis M, Batiha GE. Nanocarrier-based drug delivery systems: A way to effective diabetes management. BioNanoScience. 2025 Jun;15(2):281. https://doi.org/10.1007/s12668-025-01818-5
42. Singh LS. Developing nanocarrier-based formulations of antidiabetic drugs derived from medicinal plants: A systemic review. Pharmacological Research-Natural Products. 2024 Mar 1;2:100004. https://doi.org/10.1016/j.prenap.2023.100004
43. Kumar D, Singh AK, Kumar A, Singh H, Yadav JP, Kumar P. Bioactive‐Based Nanocarriers for Diabetes. Bioactive‐Based Nanotherapeutics. 2025 Aug 13:389-415. https://doi.org/10.1002/9781394287345.ch12
44. Guo S, Li H. Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment. Journal of Fluorescence. 2025 Jun;35(6):3895-904. https://doi.org/10.1007/s10895-024-03810-w PMid:38888657
45. Sarkhel S, Shuvo SM, Ansari MA, Mondal S, Kapat P, Ghosh A, Sarkar T, Biswas R, Atanase LI, Carauleanu A. Nanotechnology-based approaches for the management of diabetes mellitus: an innovative solution to long-lasting challenges in antidiabetic drug delivery. Pharmaceutics. 2024 Dec 9;16(12):1572. https://doi.org/10.3390/pharmaceutics16121572 PMid:39771551 PMCid:PMC11678074
46. Jahangir MA, Khan R, Sarim Imam S. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Artificial cells, nanomedicine, and biotechnology. 2018 Oct 31;46(sup1):66-78. https://doi.org/10.1080/21691401.2017.1411933 PMid:29226729
47. Nazief AM, Hassaan PS, Khalifa HM, Sokar MS, El-Kamel AH. Lipid-based gliclazide nanoparticles for treatment of diabetes: formulation, pharmacokinetics, pharmacodynamics and subacute toxicity study. International journal of nanomedicine. 2020 Feb 18:1129-48. https://doi.org/10.2147/IJN.S235290 PMid:32110012 PMCid:PMC7038779
48. Mishra R, Pal R, Khan Z, Sahoo S, Chawra HS, Kumar D. Solid lipid nanoparticles (SLNPs): a state-of-the-art formulation strategy and their applications against tuberculosis (TB) and analgesic effects. Nanoscience & Nanotechnology-Asia. 2025 Jun;15(3):E22106812379362. https://doi.org/10.2174/0122106812379362250602075954
49. Hu M, Gou T, Chen Y, Xu M, Chen R, Zhou T, Liu J, Peng C, Ye Q. A novel drug delivery system: hyodeoxycholic acid-modified metformin liposomes for type 2 diabetes treatment. Molecules. 2023 Mar 8;28(6):2471. https://doi.org/10.3390/molecules28062471 PMid:36985444 PMCid:PMC10055618
50. Pandey S, Shamim A, Shaif M, Kushwaha P. Development and evaluation of Resveratrol-loaded liposomes in hydrogel-based wound dressing for diabetic foot ulcer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023 Aug;396(8):1811-25. https://doi.org/10.1007/s00210-023-02441-5 PMid:36862150
51. Zhang K, Chen J, Raza F, Zafar H, Xu Y, Li R, Ullah KH, Zhou S. Advancing diabetes treatment: novel formulation of polydatin long-circulating liposomes and their glucose-regulating impact on hyperlipidemia-induced type 2 diabetic mice. Materials Advances. 2024;5(16):6516-34. https://doi.org/10.1039/D4MA00020J
52. Abou-Taleb HA, Aldosari BN, Zaki RM, Afzal O, Tulbah AS, Shahataa MG, Abo El-Ela FI, Salem HF, Fouad AG. Formulation and therapeutic evaluation of isoxsuprine-loaded nanoparticles against diabetes-associated stroke. Pharmaceutics. 2023 Aug 30;15(9):2242. https://doi.org/10.3390/pharmaceutics15092242 PMid:37765211 PMCid:PMC10536800
53. Vasanth S, Mishra R, Sahoo S, Parveen S, Khan Z, Mumtaz, Ruqaiya, Pal R. Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration. Current aging science. 2025.
54. Sasidharan J, Meenakshi RV, SureshKumar P. Green synthesis, Characterization and Evaluation of In-vitro Antioxidant & Anti-diabetic Activity of Nanoparticles from A Polyherbal Formulation-Mehani. J. Environ. Nanotechnol. 2018;7(3):51-9. https://doi.org/10.13074/jent.2018.09.183316
55. Khatri N, Vaja PN, Krishna MM, BM K, Narapusetty N, Gogoi P, Sharma RK, Jahnavi P. Formulation and Evaluation of Metformin-Loaded Nanoparticles for Enhanced Oral Bioavailability and Antidiabetic Activity. International Journal of Environmental Sciences. 2025;11(19s):2025.
56. Dixit PV, Mishra DK, Sharma S, Gautam RK. Nanocarriers and diabetes: new vistas and the way ahead. Current Pharmaceutical Biotechnology. 2023 Sep 1;24(11):1420-9. https://doi.org/10.2174/1389201024666221227140728 PMid:36578251
57. Abdel‐Moneim A, Ramadan H. Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management. Drug Development Research. 2022 Apr;83(2):301-16. https://doi.org/10.1002/ddr.21903 PMid:34859477
58. Singh LS. Developing nanocarrier-based formulations of antidiabetic drugs derived from medicinal plants: A systemic review. Pharmacological Research-Natural Products. 2024 Mar 1;2:100004. https://doi.org/10.1016/j.prenap.2023.100004
59. Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, Maringhini G, van Lier A, Haagsma JA, Havelaar AH, Kramarz P. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Eurosurveillance. 2018 Apr 19;23(16):17-00454. https://doi.org/10.2807/1560-7917.ES.2018.23.16.17-00454 PMid:29692315 PMCid:PMC5915974
60. Haagsma JA, Graetz N, Bolliger I, Naghavi M, Higashi H, Mullany EC, Abera SF, Abraham JP, Adofo K, Alsharif U, Ameh EA. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Injury prevention. 2016 Feb;22(1):3-18.
61. Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders?. The EMBO Reports. 2016 Sep 1;17(9):1245-9. https://doi.org/10.15252/embr.201642951 PMid:27491723 PMCid:PMC5007565
62. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, Specchia ML, Laurenti P, Damiani G. Impact of the burden of COVID-19 in Italy: results of disability-adjusted life years (DALYs) and productivity loss. International journal of environmental research and public health. 2020 Jun;17(12):4233. https://doi.org/10.3390/ijerph17124233 PMid:32545827 PMCid:PMC7345321
63. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, Casey DC, Charlson FJ, Coates MM, Coggeshall M, Cornaby L. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016 Oct 8;388(10053):1603-58.
64. Pal, Rahul & Koli, Manju & Shah, Tapaskumar & Dutta, Prottay & Ghosh, Binita & Patel, Neetu & Patel, Abhay & Singh, Akashdeep. (2025). Non-Ionic Surfactants (NIOs) in Niosome Drug Delivery: In-Depth Review on Clinical Trials, Patents in Tuberculosis (TB) and Oncology. Current Nanomedicine. 16. https://doi.org/10.2174/0124681873413153251014082026
65. Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine. 2022 Dec 1;54. https://doi.org/10.1016/j.eclinm.2022.101675 PMid:36193171 PMCid:PMC9526145
66. Chu DT, Nguyet NT, Dinh TC, Lien NV, Nguyen KH, Ngoc VT, Tao Y, Son LH, Le DH, Nga VB, Jurgoński A. An update on physical health and economic consequences of overweight and obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018 Nov 1;12(6):1095-100. https://doi.org/10.1016/j.dsx.2018.05.004 PMid:29799416
67. Alcaraz A, Bardach AE, Espinola N, Perelli L, Rodriguez Cairoli F, La Foucade A, de Mello Vianna CM, Guevara G, Gittens-Baynes KA, Johns P, Beharry V. Health and economic burden of disease of sugar-sweetened beverage consumption in four Latin American and Caribbean countries: a modelling study. BMJ open. 2023 Feb;13(2):e062809. https://doi.org/10.1136/bmjopen-2022-062809 PMid:36750287 PMCid:PMC9906178
68. Stevens B, Pezzullo L, Verdian L, Tomlinson J, George A, Bacal F. The economic burden of heart conditions in Brazil. Arquivos brasileiros de cardiologia. 2018;111:29-36. https://doi.org/10.5935/abc.20180104 PMid:30110042 PMCid:PMC6078379
69. Gupta U, Kosey S, Pal R. Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. Journal of Drug Delivery Science and Technology. 2025 Sep 1;111:107181. https://doi.org/10.1016/j.jddst.2025.107181
70. Diabetes GB, Fischer F, Moraga P, Ribeiro D, Violante FS, Schmidt MI, Sadeghi E, Kimokoti RW, Kivimäki M, Khafaie MA, Bijani A. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2· 5 air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. The lancet/Planetary health. 2022;6(DKFZ-2022-02796):e586-600.
71. Burkart K, Causey K, Cohen AJ, Wozniak SS, Salvi DD, Abbafati C, Adekanmbi V, Adsuar JC, Ahmadi K, Alahdab F, Al-Aly Z. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2· 5 air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. The Lancet Planetary Health. 2022 Jul 1;6(7):e586-600.
72. Pal, Rahul & Ghosh, Binita & Dutta, Prottay & Kumar, Amar & Sahoo, Subhashree & Mishra, Rakhi. (2026). Lipidic Nanocarriers (Liposomes): A Potential Targeting Strategy for Cosmeceutical Applications and Therapeutic Applications-An In-Depth Review. Current Nanomedicine. 16. https://doi.org/10.2174/0124681873411316251118051648
73. Xie J, Wang M, Long Z, Ning H, Li J, Cao Y, Liao Y, Liu G, Wang F, Pan A. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. Bmj. 2022 Dec 7;379. https://doi.org/10.1136/bmj-2022-072385 PMid:36740855 PMCid:PMC9727920
74. Wang W, Hu M, Liu H, Zhang X, Li H, Zhou F, Liu YM, Lei F, Qin JJ, Zhao YC, Chen Z. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell metabolism. 2021 Oct 5;33(10):1943-56. https://doi.org/10.1016/j.cmet.2021.08.005 PMid:34478633
75. Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016. Diabetes care. 2020 May 1;43(5):964-74. https://doi.org/10.2337/dc19-1614 PMid:32139380
76. Abdul Basith Khan M, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. Journal of epidemiology and global health. 2020 Mar;10(1):107-11.https://doi.org/10.2991/jegh.k.191028.001 PMid:32175717 PMCid:PMC7310804
77. Shukla K, Vasanth S, Mishra R, Sahoo S, Saxena G, Shah TM, et al. Nanoparticles (NPs) as a cutting-edge therapeutic strategy and their current status in tuberculosis (TB): a comprehensive review. Recent Adv Drug Deliv Formul. 2026;20:1-49. https://doi.org/10.2174/0126673878403646251209194351 PMid:41968556
78. Awad SF, A Toumi A, A Al-Mutawaa K, A Alyafei S, A Ijaz M, AH Khalifa S, B Kokku S, CM Mishra A, V Poovelil B, B Soussi M, G El-Nahas K. Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis. BMJ Open Diabetes Research & Care. 2022 Apr;10(2):e002704. https://doi.org/10.1136/bmjdrc-2021-002704 PMid:35443971 PMCid:PMC9021773
79. Pal, Rahul & Mandal, Raj & Shah, Tapaskumar & Singh, Anjali & Sahoo, Subhashree. (2026). Gastro-Retentive Drug Delivery Systems (GRDDs) as a Promising Strategy for Disease Targeting: A Comprehensive Review. Drug Delivery Letters. 10.2174/0122103031410778251206145139.
80. Liang R, Long J, Zheng Q, Yuan G, Chen X, Xin Z, Lai F, Liu Y. Current landscape of type 1 diabetes mellitus-related interventional clinical trials registered on ClinicalTrials. gov: a cross-sectional study. Acta Diabetologica. 2021 Jun;58(6):723-33. https://doi.org/10.1007/s00592-020-01627-0 PMid:33543370
81. Singh JV, Bedi PM, Singh H, Sharma S. Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). Expert Opinion on Therapeutic Patents. 2020 Oct 2;30(10):769-80. https://doi.org/10.1080/13543776.2020.1811233 PMid:32797760
82. Litvinova O, Klager E, Tzvetkov NT, Kimberger O, Kletecka-Pulker M, Willschke H, Atanasov AG. Digital pills with ingestible sensors: patent landscape analysis. Pharmaceuticals. 2022 Aug 19;15(8):1025. https://doi.org/10.3390/ph15081025 PMid:36015173 PMCid:PMC9415622
83. Ghosh, Binita & Sharma, Pratiksha & Goyal, Saloni & Chaturvedi, Varunesh & Reena, Km & Pal, Rahul. (2026). Next-Generation Nanocarriers-Based Nanoformulations for Polycystic Ovary Syndrome (PCOS): A Deep Insight into Clinical and Patents Perspectives. Drug Delivery Letters. 16. https://doi.org/10.2174/0122103031426128260310065402
84. Karachaliou F, Simatos G, Simatou A. The challenges in the development of diabetes prevention and care models in low-income settings. Frontiers in endocrinology. 2020 Aug 13;11:518. https://doi.org/10.3389/fendo.2020.00518 PMid:32903709 PMCid:PMC7438784
85. Avilés-Santa ML, Monroig-Rivera A, Soto-Soto A, Lindberg NM. Current state of diabetes mellitus prevalence, awareness, treatment, and control in Latin America: challenges and innovative solutions to improve health outcomes across the continent. Current diabetes reports. 2020 Nov;20(11):62. https://doi.org/10.1007/s11892-020-01341-9 PMid:33037442 PMCid:PMC7546937
86. Pati MK, Swaroop N, Kar A, Aggarwal P, Jayanna K, Van Damme W. A narrative review of gaps in the provision of integrated care for noncommunicable diseases in India. Public Health Reviews. 2020 May 13;41(1):8. https://doi.org/10.1186/s40985-020-00128-3 PMid:32435518 PMCid:PMC7222468
87. Godman B, Basu D, Pillay Y, Mwita JC, Rwegerera GM, Anand Paramadhas BD, Tiroyakgosi C, Okwen PM, Niba LL, Nonvignon J, Sefah I. Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across Africa and the implications for the future. Frontiers in pharmacology. 2020 Mar 20;11:108. https://doi.org/10.3389/fphar.2020.00108 PMid:32265688 PMCid:PMC7098994
88. Mohseni M, Ahmadi S, Azami-Aghdash S, Isfahani HM, Moosavi A, Fardid M, Etemadi M, Ghazanfari F. Challenges of routine diabetes care during COVID-19 era: a systematic search and narrative review. Primary care diabetes. 2021 Dec 1;15(6):918-22. https://doi.org/10.1016/j.pcd.2021.07.017 PMid:34393092 PMCid:PMC8326007
89. Flor LS, Wilson S, Bhatt P, Bryant M, Burnett A, Camarda JN, Chakravarthy V, Chandrashekhar C, Chaudhury N, Cimini C, Colombara DV. Community-based interventions for detection and management of diabetes and hypertension in underserved communities: a mixed-methods evaluation in Brazil, India, South Africa and the USA. BMJ Global Health. 2020 Jun;5(6):e001959. https://doi.org/10.1136/bmjgh-2019-001959 PMid:32503887 PMCid:PMC7279660
90. Nadeem MW, Goh HG, Hussain M, Liew SY, Andonovic I, Khan MA. Deep learning for diabetic retinopathy analysis: a review, research challenges, and future directions. Sensors. 2022 Sep 8;22(18):6780. https://doi.org/10.3390/s22186780 PMid:36146130 PMCid:PMC9505428
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Rashmi Khanijau , Mona Rajiv Kukkar , Ena Trehan , Priya Singh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.